NORDION INC. $12 (Toronto symbol NDN; Aggressive Growth Portfolio, Consumer sector; Shares outstanding: 61.9 million; Market cap: $742.8 million; Price-to-sales ratio: 2.7; Dividend suspended in September 2012; TSINetwork Rating: Extra Risk; www.nordion.com) sells isotopes for cancer detection and research. It also makes products that sterilize food and surgical tools.
In its fiscal 2014 first quarter, which ended January 31, 2014, Nordion’s earnings jumped to $36.5 million, or $0.59 a share (all amounts except share price and market cap in U.S. dollars). A year earlier, it earned $2.9 million, or $0.05 a share. The gain was partly due to positive exchange rates, which added $0.31 to the latest per-share earnings.
These figures exclude unusual items, such as costs related to the company’s strategic review. As part of this process, Nordion sold its Targeted Therapies division for $190 million in July 2013. This business makes TheraSphere, a process for treating liver cancer using millions of microscopic glass beads containing radioactive materials.
Revenue from ongoing operations rose 70.1%, to $70.9 million from $41.6 million. The temporary shutdown of a reactor in Europe cut its competitors’ supplies of certain isotopes, prompting more buyers to purchase from Nordion. As a result, revenue at the company’s isotope division (which supplies 73% of the total) jumped 105.1%.
Revenue from the sterilization technologies business (27%) gained 16.6%.
Nordion recently signed several long-term contracts to sell isotopes to medical device makers and other customers. These agreements should increase the isotope division’s revenue by 40% in fiscal 2014. The company also expects full-year revenue from sterilization products to increase between 10% and 15%.
However, the stock will remain volatile until Nordion completes its strategic review, probably by the end of fiscal 2014.
Nordion is still a hold.